Debjit Chattopadhyay's Stock Ratings

Guggenheim Analyst

Debjit Chattopadhyay is an analyst at Guggenheim. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/16/2024

Overall Average Return

4.24%

Smart Score

59%

Overall Average Return Percentile

46th

Number of Ratings

31
Buy NowGet Alert
05/14/2024FOLDBuy Now
Amicus Therapeutics
$9.4637.42% → $13UpgradeNeutral → BuyGet Alert
04/30/2024DTILBuy Now
Precision BioSciences
$11.8061.02% → $19Initiates → BuyGet Alert
04/18/2024VRTXBuy Now
Vertex Pharmaceuticals
$440.642.12%$445 → $450MaintainsBuyGet Alert
03/26/2024VYGRBuy Now
Voyager Therapeutics
$8.55157.31% → $22Initiates → BuyGet Alert
03/07/2024DYNBuy Now
Dyne Therapeutics
$28.7528.7%$33 → $37MaintainsBuyGet Alert
03/05/2024PRMEBuy Now
Prime Medicine
$7.04184.09%$24 → $20MaintainsBuyGet Alert
02/27/2024KRYSBuy Now
Krystal Biotech
$163.786.85%$130 → $175MaintainsBuyGet Alert
01/18/2024NAMSBuy Now
NewAmsterdam Pharma
$20.0549.63% → $30Initiates → BuyGet Alert
11/21/2023SLNOBuy Now
Soleno Therapeutics
$45.66-12.4% → $40Assumes → BuyGet Alert
09/13/2023BMRNBuy Now
Biomarin Pharmaceutical
$76.9742.91% → $110ReiteratesBuy → BuyGet Alert
08/15/2023CNTABuy Now
Centessa Pharmaceuticals
$8.8313.25%$9 → $10MaintainsBuyGet Alert
07/31/2023PRMEBuy Now
Prime Medicine
$7.04240.91% → $24Initiates → BuyGet Alert
06/12/2023CNTABuy Now
Centessa Pharmaceuticals
$8.831.93% → $9Initiates → BuyGet Alert
05/22/2023KRYSBuy Now
Krystal Biotech
$163.78-20.63%$101 → $130MaintainsBuyGet Alert
05/02/2023VRTXBuy Now
Vertex Pharmaceuticals
$440.64-12.63%$339 → $385MaintainsBuyGet Alert
04/27/2023BMRNBuy Now
Biomarin Pharmaceutical
$76.9755.9%$125 → $120MaintainsBuyGet Alert
02/28/2023QUREBuy Now
uniQure
$5.07945.36% → $53Reiterates → BuyGet Alert
02/28/2023KRYSBuy Now
Krystal Biotech
$163.78-38.33% → $101Reiterates → BuyGet Alert
02/28/2023BMRNBuy Now
Biomarin Pharmaceutical
$76.9762.4% → $125Reiterates → BuyGet Alert
01/26/2023DYNBuy Now
Dyne Therapeutics
$28.7514.78% → $33Initiates → BuyGet Alert
11/21/2022ALLOBuy Now
Allogene Therapeutics
$3.00866.67%$43 → $29MaintainsBuyGet Alert
11/11/2022PASGBuy Now
Passage Bio
$1.34720.9%$13 → $11MaintainsBuyGet Alert
10/13/2022RAREBuy Now
Ultragenyx Pharmaceutical
$44.2512.98% → $50UpgradeNeutral → BuyGet Alert
06/27/2022ALNYBuy Now
Alnylam Pharmaceuticals
$151.22——DowngradeBuy → NeutralGet Alert
03/01/2022IONSBuy Now
Ionis Pharmaceuticals
$37.6270.12% → $64Initiates → BuyGet Alert
01/31/2022SRRABuy Now
Sierra Oncology
——$35 → $51MaintainsBuyGet Alert
01/05/2022BEAMBuy Now
Beam Therapeutics
$23.79446.45% → $130Initiates → BuyGet Alert
12/16/2021TSHABuy Now
Taysha Gene Therapies
$3.09805.59%—Initiates → BuyGet Alert
12/01/2021VRTXBuy Now
Vertex Pharmaceuticals
$440.64-35.09%$250 → $286MaintainsBuyGet Alert
06/01/2021TALSBuy Now
Talaris Therapeutics
—— → $260Initiates → BuyGet Alert

Recent Analyst Stock Rating News

Deep Dive Into Precision BioSciences Stock: Analyst Perspectives (4 Ratings)
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today.
Tesla To $123? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Krystal Biotech Analysts Increase Their Forecasts Following Q4 Results
Krystal Biotech, Inc. (NASDAQ: KRYS) reported better-than-expected financial results for its fourth quarter on Monday.
Benzinga's Daily Brief On Trending Tickers For March 2, 2022: VanEck Russia ETF, AMC Entertainment, SoFi Technologies And More
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks. The data on the trending tickers is compiled from a list of most-discussed tickers on the popular Reddit forum WallStreetBets.
72 Biggest Movers From Yesterday
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 85.8% to settle at $10.22 on above-average volume.
Why Guggenheim Is Bullish On Passage Bio
Passage Bio Inc (NASDAQ: PASG) is leveraging the UPenn Gene Therapy Program to access compelling translational research and develop a range of differentiated adeno-associated virus gene therapies for rare central nervous system disorders, according to Guggenheim.
5 ASCO Abstracts Moving Biopharma Stocks
The American Society of Clinical Oncology annual conference brings together oncology professionals, patient advocates, industry representatives, and major media outlets from across the globe. This year's meeting is is scheduled for May 29-31 and is organized as a virtual event due to the lockdowns and stay-at-home restrictions necessitated by the COVID-19 pandemic.
Analyst: Sarepta's DMD Gene Therapy Results 'Dramatic And Far Exceeding Expectations'
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free